Different Activation of TRAF4 and TRAF6 in Inflammatory Bowel Disease

Table 1

Characteristics of included subjects.

	CD (𝑛=40)	UC (𝑛=42)	HC (40)
Gender (female/male)	21/19	20/22	20/20
Age (years)	33.58 (28.87–38.28)	41.64 (37.18–46.10)	35.48 (30.06–40.89)
BMI (kg/m^2)	19.29 (18.81–19.76)***	20.00 (19.41–20.59)***	22.84 (22.10–23.58)
Smoking (yes/no)	8/32	22/20**	3/37
Extent
Ileitis	3
Ileocolitis	15
Colitis	22
Proctosigmoiditis		13
Left-sided colitis		20
Pancolitis		9
Therapy
5-ASA/SASP	36	42
Glucosteroids	22	16
AZA	8	6
Infliximab	6	1
Surgery	1	1
Endoscopic score^†	3.200 (1.650–6.000)	2.000 (1.000–3.000)

CD: Crohn’s disease; UC: ulcerative colitis; HC: healthy controls; BMI: body mass index; 5-ASA: 5-aminosalicylic acid; SASP: sulfasalazine; AZA: azathioprine; ***𝑃<0.0001, significance is the difference from healthy controls; **𝑃<0.01, significance is the difference from patients with Crohn’s disease; ^†values are medians and 25%–75% percentile, simplified endoscopic score in Crohn's disease (SES-CD) is used to validate endoscopic severity in Crohn's disease, and Baron score is used to validate endoscopic severity in ulcerative colitis, respectively.